Amsurg Corp

Amsurg — Merger or Acquisition (May 2014)

27 slides from Amsurg's merger presentation, May 29, 2014

  1. Slide 1: AMSURG's Acquisition of Sheridan Healthcare Investor Presentation

    Exhibit 99.2 AMSURG's Acquisition of Sheridan Healthcare Investor Presentation May 29, 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding AMSURG’s

  3. Slide 3: Presenters

    Presenters Chris Holden Claire Gulmi Chief Executive Officer Chief Financial Officer AMSURG AMSURG John Carlyle Robert Coward Chief Executive Officer President Sheridan Healthcare Sheridan Healthcare 2

  4. Slide 4: Agenda

    Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG

  5. Slide 5: Agenda: Transaction Overview

    Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG

  6. Slide 6: AMSURG has agreed to acquire Sheridan Healthcare, a portfolio company of Hellman & Friedman

    AMSURG has agreed to acquire Sheridan Transaction is immediately and significantly Healthcare, a portfolio company of Hellman & accretive to Adjusted EPS (2) and Adjusted Friedman, in a transaction valued at $2,350mm EPS growth rate and meaningfully – LTM 3/31/2014 Sheridan PF Adj Revenue and PF Adj

  7. Slide 7: Key Deal Terms

    Key Deal Terms Transaction $2,350mm total purchase price Consideration Funded with cash and AMSURG equity currently valued at approximately $615mm AMSURG may replace a substantial portion of equity consideration with cash by accessing the equity or equity-linked markets between signing and closing H

  8. Slide 8: Combination Enhances Diversity, Scale And Payer Mix

    Combination Enhances Diversity, Scale And Payer Mix ($ in millions) Pro Forma States 34 25 38 Facilities / Locations >240 >300 >540 Physicians ~3,500 ~1,100 ~4,600 LTM Revenue $1,080 $1,082 (2) $2,162 LTM Pro Forma Adj. EBITDA (1) $187 (2) $193 (2) $380 LTM Free Cash Flow $116 $91 $207 Government Pa

  9. Slide 9: Investment Thesis

    Investment Thesis Combines Two Best in Class Organizations in Complementary and Adjacent Markets Catalytic to Total and Organic Growth Potential Differentiated and Diversified Revenue and Growth Synergies Significantly Enhances M&A Opportunities Responsive To Key Trends In Healthcare 6

  10. Slide 10: Agenda: Sheridan Overview

    Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG

  11. Slide 11: Sheridan Healthcare – Leader in Outsourced Physician Services

    Sheridan Healthcare – Leader in Outsourced Physician Services Emergency Medicine Anesthesiology Children’s Services Radiology Services #1 and most experienced #2 provider in the US A leading provider in the A leading national provider in the US US provider to hospitals Services include: >1,500 anest

  12. Slide 12: Sheridan Overview

    Sheridan Overview Leading national provider of multi-specialty, Revenue outsourced physician services ($ in millions) Pro Forma Impact of Acquisitions $1,082 – Founded in 1962 $836 $919 $762 – Tenured management team $684 – #1 share in Anesthesiology $954 – #2 share in Children’s Services – Leader i

  13. Slide 13: Leadership in Large and Fragmented Markets

    Leadership in Large and Fragmented Markets Anesthesiology Emergency Services Radiology Children’s Services Market Size $25 billion $10 billion $14 billion $3 billion Sheridan Leadership No. 1 Market leader in Radiology and Emergency Services No. 2 Position Envision Sheridan 2% Team Health Envision E

  14. Slide 14: Agenda: The New AMSURG

    Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG

  15. Slide 15: Track Record of Successful Evolution and Change

    Track Record of Successful Evolution and Change GI / Single-Specialty Focus Diversified ASC Provider Integrating Services Addressable 2007: ~$5bn 2013: ~$15bn 2014: ~$70bn Market: Leading operator of single- Diversified into multi-specialty Natural evolution and integration of specialty ASCs (Largel

  16. Slide 16: Market Forces Driving Differentiation

    Market Forces Driving Differentiation Narrow Networks + Increasing Physician Employment Consolidation Vertical integration – particularly around the surgical episode of care PFP / Bundled Payments / Risk Better infrastructure and expertise to address trend toward physician Vertical Integration emplo

  17. Slide 17: Combination Drives New Growth Synergies

    Combination Drives New Growth Synergies New Contract Wins New Health System / ASC Joint Ventures Collaborative Vertical Integration with AMSURG ASC Portfolio 12

  18. Slide 18: Leverage AMSURG Footprint To Accelerate New Contract Wins

    Leverage AMSURG Footprint To Accelerate New Contract Wins AMSURG has built scale and presence in over 100 markets Combines a highly desired provider portfolio with a hospital based physician solution AMSURG footprint extends Sheridan’s reach into 13 new states Strategy yields a more comprehensive ho

  19. Slide 19: Advances New Hospital / ASC Joint Venture Strategy

    Advances New Hospital / ASC Joint Venture Strategy Physician Surgical Centers Outsourcing + Differentiated Engagement With Health Systems AMSURG currently in discussions with leading health Combined offering provides opportunity for robust systems in nearly half of all markets dialogue with decision

  20. Slide 20: Clinical Integration of Anesthesia / ASC Portfolio

    Clinical Integration of Anesthesia / ASC Portfolio ASC Anesthesia Market The AMSURG Portfolio • Substantial addressable outpatient • >$250mm anesthesia revenue anesthesia market associated with current AMSURG portfolio • Trend towards surgical volume migration to outpatient setting • >95% of AMSURG

  21. Slide 21: Transaction Creates a Multi-Levered Growth Profile

    Transaction Creates a Multi-Levered Growth Profile Pro Forma Revenue Growth Breakdown Pro Forma Growth Drivers Acquisitions Differentiated and Diversified Organic Growth Same Store Growth Organic New Contract Wins Addressable Market Expanded From $15bn to ~$70bn Status Quo Wall Street Pro Forma Cons

  22. Slide 22: Robust Cash Flow Creation and Deleveraging Capability

    Robust Cash Flow Creation and Deleveraging Capability Attractive Free Cash Flow Profile and Disciplined Approach to Leverage Recurring revenue and scale drive strong and predictable cash flows – Pro forma margins of 18%; limited bad debt expense Limited capital expenditures relative to other provide

  23. Slide 23: Conclusion

    Conclusion Combines Two Best in Class Organizations in Complementary and Adjacent Markets Catalytic to Total and Organic Growth Potential Differentiated and Diversified Revenue and Growth Synergies Significantly Enhances M&A Opportunities Responsive To Key Trends In Healthcare 18

  24. Slide 24: Q&A

    Q&A

  25. Slide 25: Appendix

    Appendix

  26. Slide 26: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures ($ in millions) Revenue Reconciliation Free Cash Flow Last Twelve Months Last Twelve Months as of March 31, 2014 Year Ended December 31, 2011 as of March 31, 2014 Sheridan AMSURG Sheridan Combined AMSURG Sheridan Combined Revenues $954 Operating cash flow $243 $82

  27. Slide 27: Reconciliation of Non-GAAP Measures (cont'd)

    Reconciliation of Non-GAAP Measures (cont’d) ($ in millions) EBITDA Last Twelve Months as of March 31, 2014 AMSURG Sheridan Total Net Income $72 $13 $85 Interest 29 55 84 Taxes 50 18 68 Depreciation and amortization 33 37 70 EBITDA $184 $123 $307 Proforma EBITDA of acquisitions 5 38 43 Restructuring

AMSURG — Merger or Acquisition (May 2014) on 6ix